Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease

Mahmoud A. AbdelRazek, M Casasola, Roohallah Mollashahi, Alexander Brodski, S.J. Morin, Aleksandra Augustynowicz, Sarmad Jassim, Marcelo Matiello, Jacob A. Sloane